This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

GLP-1 highs and lows continue in US for Novo Nordisk

By Melissa Ritti ( January 27, 2026, 21:22 GMT | Insight) -- Because Novo Nordisk competes directly with compounding pharmacies in the semaglutide market it has statutory and Article III standing to assert false advertising, a US judge ruled Monday. The win follows class claims from three days earlier alleging that the Danish drugmaker engaged in an anticompetitive scheme to keep generic alternatives for a different GLP-1 drug off the market.Novo Nordisk is starting 2026 much the same way it ended 2025 — knee deep in litigation over its blockbuster glucagon-like peptide-1 (GLP-1) drugs....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections